<!DOCTYPE html>
<!--
==============================================================================
           "GitHub HTML5 Pandoc Template" v2.1 — by Tristano Ajmone           
==============================================================================
Copyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:

- https://github.com/tajmone/pandoc-goodies

The CSS in this template reuses source code taken from the following projects:

- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):
  https://github.com/sindresorhus/github-markdown-css

- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):
  http://primercss.io/

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
The MIT License 

Copyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)
Copyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)
Copyright (c) 2017 GitHub Inc.

"GitHub Pandoc HTML5 Template" is Copyright (c) Tristano Ajmone, 2017, released
under the MIT License (MIT); it contains readaptations of substantial portions
of the following third party softwares:

(1) "GitHub Markdown CSS", Copyright (c) Sindre Sorhus, MIT License (MIT).
(2) "Primer CSS", Copyright (c) 2016 GitHub Inc., MIT License (MIT).

Permission is hereby granted, free of charge, to any person obtaining a copy
of this software and associated documentation files (the "Software"), to deal
in the Software without restriction, including without limitation the rights
to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
copies of the Software, and to permit persons to whom the Software is
furnished to do so, subject to the following conditions:

The above copyright notice and this permission notice shall be included in all
copies or substantial portions of the Software.

THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE
SOFTWARE.
==============================================================================-->
<html>
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <title>Liver disease MeG-CLS-031</title>
  <style type="text/css">
@charset "UTF-8";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,"Segoe UI",Helvetica,Arial,sans-serif,"Apple Color Emoji","Segoe UI Emoji","Segoe UI Symbol";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:""}.markdown-body hr::after{display:table;clear:both;content:""}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:" "}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:""}.markdown-body::after{display:table;clear:both;content:""}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}
  </style>
  <style type="text/css">code{white-space: pre;}</style>
  <!--[if lt IE 9]>
    <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js"></script>
  <![endif]-->
</head>
<body>
<article class="markdown-body">
<h1 id="liver-disease">Liver disease</h1>
<h2 id="executive-summary"><em>Executive summary</em></h2>
<h2 id="introduction">Introduction</h2>
<p>The liver is responsible for many critical functions within the body and should it become diseased or injured, the loss of those functions can cause significant damage to the body. Liver disease is a broad term that covers all the potential problems that cause the liver to fail to perform its designated functions. Usually, more than 75% or three quarters of liver tissue needs to be affected before a decrease in function occurs.</p>
<p>Management of these patients is divided into the assessment and treatment of patients with a new diagnosis of liver disease and that of those with established chronic liver disease (CLD) who have decompensated.</p>
<h2 id="target-user">Target User</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Doctors</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Nurses</p>
</div></li>
</ul>
<h2 id="target-area-of-use">Target area of use </h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Ward</p>
</div></li>
</ul>
<h2 id="key-areas-of-focusnew-additionschanges">Key areas of focus/new additions/changes</h2>
<p>This guideline outlines the initial diagnosis of liver disease in our setting as well as the management of patients with established disease who decompensate.</p>
<h2 id="limitations">Limitations</h2>
<p>We have limited access to most of the diagnostic tests for causes of liver disease.</p>
<p>Access to higher level care is largely not available – except for dialysis, which might be possible at the teaching hospital.</p>
<h2 id="presenting-symptoms-and-signs">Presenting symptoms and signs</h2>
<p>If the patient is in extremis, they should be resuscitated prior to any other intervention – the most likely causes are an acute GI bleed or bacterial septicaemia.</p>
<p>Patients with liver disease can present with many different symptoms including:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Weakness and fatigue</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Jaundice</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Nausea</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Vomiting</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Weight loss</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Right upper quadrant pain</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Confusion</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Reduced GCS</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Clubbing</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Hematemesis.</p>
</div></li>
</ul>
<p>They may present with signs of anaemia, sepsis, acute liver disease or chronic liver disease.</p>
<p>The patient’s background history must be taken in order to establish the cause of the underlying liver disease. This may affect the treatment given.</p>
<p>The history of the current event must also be taken with particular note of any gastrointestinal bleeding, change in girth size, pain, confusion, difficulty breathing, increase in jaundice, recent medications and traditional treatments taken.</p>
<h2 id="examination-findings">Examination findings</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>General findings: anaemia, fever, tachycardia, altered level of consciousness or confusion, peripheral oedema.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Signs of chronic liver disease: liver flap, clubbing, palmar erythema, bruising, spider naevi, gynaecomastia, testicular atrophy, ascites, venous collaterals.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Liver: small in cirrhosis, large in acute hepatitis or neoplasm.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Splenomegaly: suggests portal hypertension.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>PR: this is essential if there is any suggestion of a GI bleed.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Signs of excess alcohol – Dupuytren’s contracture – parotid enlargement.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Stigmata of HIV: Oral thrush, Herpes Zoster scar.</p>
</div></li>
</ul>
<h2 id="investigations">Investigations</h2>
<p>Tests which may be appropriate to assess patient’s current condition include:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>FBC, LFTs, albumin, INR, U&amp;Es, blood glucose</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Urinary dipstick</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Blood cultures and chest X-ray</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Ascitic tap (if ascites is present this is essential) – send for MC&amp;S, albumin, AFBs.</p>
</div></li>
</ul>
<p>Note that FBC, INR, U&amp;Es, LFTs and ascitic tap microscopy and albumin are all urgent tests and <em><strong>the results should be reviewed within 4 hours of admission</strong></em> to the ward in any acutely unwell patient.</p>
<p>Tests to identify possible causes include:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Viral serology: HIV, HBsAg (HCV, HAV when available)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Hb genotype</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Ultrasound – for jaundiced patients ask directly about duct dilatation.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Consider autoantibodies, ferritin and AFP when available.</p>
</div></li>
</ul>
<h2 id="causes-of-decompensation-in-cld">Causes of decompensation in CLD</h2>
<p>For patients with chronic liver disease, management will depend on the cause of the decompensation. Patients with CLD may decompensate because of a complication of their underlying liver disease or because of a second insult to the liver or their overall system.</p>
<p>Complications of CLD are:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Variceal haemorrhage</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Portal vein thrombosis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Ascites</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Spontaneous bacterial peritonitis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Hepatic encephalopathy</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Hepatorenal syndrome</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Hepatopulmonary syndrome</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Hepatocellular carcinoma</p>
</div></li>
</ul>
<p>Common causes of a second insult are:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Acute viral hepatitis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Drug-induced liver injury (which may be caused by traditional treatment as well as prescribed medications)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Bacterial infection (UTI, LRI etc)</p>
</div></li>
</ul>
<h2 id="management">Management</h2>
<h3 id="newly-diagnosed-liver-disease">Newly diagnosed liver disease</h3>
<p>Treat precipitants and possible causes.</p>
<p>Ensure adequate hydration and nutrition (give e-pap if there is any doubt).</p>
<p>Avoid hepatotoxic drugs.</p>
<p>Manage according to particular complications (hepatic encephalopathy is common).</p>
<p>Seek specialist support if acute liver disease is suspected.</p>
<h3 id="all-patients-with-cld">All patients with CLD</h3>
<p>All patients admitted with CLD should have their Child-Pugh score calculated in order to provide prognostic information.</p>
<p>Use the table below to assign a score for each item:</p>
<table>
<thead>
<tr class="header">
<th><strong>Points</strong></th>
<th><strong>1</strong></th>
<th><strong>2</strong></th>
<th><strong>3</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Ascites</td>
<td>None</td>
<td>Slight</td>
<td>Moderate or above</td>
</tr>
<tr class="even">
<td>Bilirubin</td>
<td>&lt;34.2</td>
<td>34.2-51.3</td>
<td>&gt;51.3</td>
</tr>
<tr class="odd">
<td>Serum albumin</td>
<td>&gt;35</td>
<td>28-35</td>
<td>&lt;28</td>
</tr>
<tr class="even">
<td>INR</td>
<td>&lt;1.7</td>
<td>1.7-2.3</td>
<td>&gt;2.3</td>
</tr>
<tr class="odd">
<td>Encephalopathy</td>
<td>None</td>
<td>Grade 1-2</td>
<td>Grade 3-4</td>
</tr>
</tbody>
</table>
<p>Add the score and interpret the findings according to this table:</p>
<table>
<thead>
<tr class="header">
<th><strong>Class</strong></th>
<th><strong>Score</strong></th>
<th><strong>1 year survival rate</strong></th>
<th><strong>2 year survival rate</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>A</td>
<td>5-6</td>
<td>100%</td>
<td>85%</td>
</tr>
<tr class="even">
<td>B</td>
<td>7-9</td>
<td>80%</td>
<td>60%</td>
</tr>
<tr class="odd">
<td>C</td>
<td>10-15</td>
<td>45%</td>
<td>35%</td>
</tr>
</tbody>
</table>
<p>In the rare cases where the patient can control a cause of deterioration (especially alcoholic liver disease), if they remove this risk factor (i.e. stop drinking) they can improve their prognosis significantly.</p>
<p>If the INR is greater than 3.5, then vitamin K should be prescribed. In most cases, 10 mg OD orally for 3 days is adequate.</p>
<h3 id="variceal-haemorrhage">Variceal haemorrhage</h3>
<p>This should be suspected whenever there is GI bleeding. It may present with either haematemesis or melaena.</p>
<p>Other causes of GI haemorrhage are possible, but are less serious. Only 50% of bleeding varices will stop bleeding spontaneously. The outlook is even worse for patients with Child-Pugh Class C disease.</p>
<p>Re-bleeding is also very common and is more likely for older patients, those with encephalopathy, ascites, renal failure, alcoholic liver disease or low platelets.</p>
<p>Management begins with urgent fluid resuscitation including the siting of 2 large bore cannulas, iv normal saline to restore BP and urgent cross-matching of blood. Whole blood should be transfused as soon as possible aiming for an Hb of 9 g/dl.</p>
<p>Endoscopy should be arranged if available.</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Unstable patients with severe acute upper GI bleeding should be scoped as soon as possible after resuscitation.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Stable patients with upper GI bleeding should be scoped within the next working day after admission.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Any varices should be banded. If another cause of bleeding is identified, management should be altered to reflect this.</p>
</div></li>
</ul>
<p>None of the vasoactive medications shown to be effective in controlling acute bleeding are available here.</p>
<p>Patients are at high risk of concomitant infection and the presence of infection increases the risk of re-bleeding so all patients should be given prophylactic antibiotics – usually ciprofloxacin 500 mg BD for 7 days.</p>
<p>Patients are at high risk of encephalopathy and should be treated with lactulose if they are not passing stool at least twice each day – 20 ml TDS to start.</p>
<p><em>Secondary prophylaxis</em></p>
<p>This should be offered to all patients who have had a variceal bleed.</p>
<p>Both non-cardioselective beta blockers and variceal band ligation should be given.</p>
<p>Give propranolol 40 mg BD and titrate up the dose until the HR is 50-55 bpm. The maximum dose is 320 mg per day. This should also be given to patients identified as having varices who have not yet had a bleed (primary prophylaxis).</p>
<h3 id="spontaneous-bacterial-peritonitis-sbp">Spontaneous bacterial peritonitis (SBP)</h3>
<p>The signs of SBP can be very subtle and therefore it should be considered a possibility in all patients with ascites due to portal hypertension.</p>
<p>Ascitic fluid should be aspirated and sent for immediate fluid albumin and microscopy including cell count. If plenty of fluid is obtained – some can be used to inoculate blood culture bottles.</p>
<p>SBP is considered to be present if the granulocyte count is greater than 250 cells/mm3. It should be suspected if there are typical clinical signs such as Temp &gt; 37.8ºC, abdominal pain or tenderness or change in mental status.</p>
<p>As soon as the samples are obtained, if there are clinical signs of SBP, then treatment should be started. iv ceftriaxone 1 g OD or oral ciprofloxacin 500 mg BD are both appropriate empirical options. Most patients will recover with a 5 day course of treatment.</p>
<p>If the patient is on propranolol, this should be stopped permanently.</p>
<p>When the patient has recovered, they should be placed on antibiotic prophylaxis. The best choice is Septrin 960 mg OD. Ciprofloxacin 500 mg OD is an alternative.</p>
<p><span data-custom-style="Heading 3 Char"><br />
</span></p>
<p><span data-custom-style="Heading 3 Char">Hepatic encephalopathy</span></p>
<p>This is a common complication which can be difficult to diagnose in its subtler forms. It is graded according to the following table:</p>
<table>
<thead>
<tr class="header">
<th>Grade 1</th>
<th>Changes in behaviour, mild confusion, slurred speech, disordered sleep</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Grade 2</td>
<td>Lethargy, moderate confusion</td>
</tr>
<tr class="even">
<td>Grade 3</td>
<td>Marked confusion, incoherent speech, sleeping but rousable</td>
</tr>
<tr class="odd">
<td>Grade 4</td>
<td>Coma</td>
</tr>
</tbody>
</table>
<p>It may be precipitated by GI bleeding, infection (including SBP), low K<sup>+</sup>, renal failure, hypovolaemia, hypoxia, sedatives, hypoglycaemia, constipation.</p>
<p>Patients should be treated with lactulose, beginning with a dose of 20 ml TDS. The dose should be increased until they pass stools at least twice each day.</p>
<p>Any potential triggers of encephalopathy should be corrected.</p>
<h3 id="hepatorenal-syndrome">Hepatorenal syndrome</h3>
<p>This is the cause of about 15% of cases of renal failure in chronic liver disease. It refers to renal failure arising from falling renal perfusion as a direct effect of liver dysfunction. It has a very poor prognosis and there is no treatment available for it in this setting. Other causes of renal failure must therefore be excluded or treated before this diagnosis is made.</p>
<p>Consider alternative diagnoses of renal failure such as hypovolaemia, sepsis, glomerulonephritis, or obstruction.</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Dip the urine – if there are white cells or red cells, consider glomerulonephritis or a urinary infection with septic shock.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Stop any diuretics.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Give 1 litre of normal saline over 1-2 hours and monitor urinary output and observations. If the renal failure is caused by hypovolaemia, you should see an increase in urine output and improving observations.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Treat any infection.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Arrange for a renal and bladder ultrasound to exclude obstruction.</p>
</div></li>
</ul>
<p>Any patient who has no other diagnosis identified and who has not had an improvement in their renal function with these interventions may have hepatorenal syndrome. The diagnosis can be confirmed if the creatinine rises by 25 or more within 48 hours or if there is a 50% rise from baseline within 7 days. The treatment is supportive. A small number will recover if they can be supported until their liver function improves.</p>
<h3 id="hepatopulmonary-syndrome">Hepatopulmonary syndrome</h3>
<p>Diagnosed when a patient with CLD becomes hypoxic and is found to have a hyperdynamic circulation. They may become hypoxic only on sitting upright.</p>
<p>Treat with oxygen and exclude other causes of hypoxia. There is no specific treatment and the prognosis is very poor.</p>
<h3 id="ascites">Ascites</h3>
<p>Ascites is a very common complication of chronic liver disease. It is usually diagnosed clinically and confirmed by abdominal ultrasound.</p>
<p>All CLD patients presenting with ascites should have an immediate ascitic tap with samples sent for albumin, cell count and culture.</p>
<p>Calculate the serum ascites albumin gradient (SAAG):</p>
<p>SAAG = serum albumin – ascites albumin</p>
<p>If SAAG is greater than 11, the ascites is caused by portal hypertension – usually because of liver disease, but could be due to heart failure or Budd-Chiari syndrome. If SAAG is less than 11, an alternative diagnosis must be sought.</p>
<p>If the cell count shows &gt; 250 granulocytes/mm<sup>3</sup>, then the patient has SBP and should be treated accordingly.</p>
<p>Ascites that is due to portal hypertension in the context of CLD should be treated with salt restriction and diuretics. Start with 40 mg furosemide OD and 100 mg spironolactone OD. If there is no response after 3-5 days, the doses can be increased in the same ratio up to a maximum of 160 mg furosemide and 400 mg spironolactone. A patient with ascites and oedema may lose up to 2 kg/day whilst a patient with only ascites typically loses no more than 0.75 kg/day.</p>
<p>If the ascites is tense or the ascites needs to be removed more quickly, large volume paracentesis can be undertaken. Up to 5 litres can be removed each day without replacement with albumin or other fluids.</p>
<p><em><strong>Patients who develop ascites should not continue treatment with propranolol or an ACE inhibitor.</strong></em></p>
<h3 id="hepatocellular-carcinoma">Hepatocellular carcinoma</h3>
<p>In our setting, many patients do not present with CLD until they already have a large hepatocellular carcinoma. There is little that can be done to treat them apart from symptom control.</p>
<p>Patients with CLD who present with a sudden deterioration in liver function may have developed a HCC and should be sent for ultrasound. If a new HCC is present, they should be referred to the liver clinic for assessment once they have recovered from their acute decompensation.</p>
<p>Patients should be treated with analgesia according to the WHO analgesic ladder if they are in pain. Paracetamol is safe in this setting. NSAIDs should be used with caution, but are the most effective option for pain due to stretching of the liver capsule. Codeine and morphine may trigger hepatic encephalopathy, but should be used if the patient’s pain is severe and unresponsive to other options.</p>
<h2 id="key-issues-for-nursing-care">Key Issues for Nursing care</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Refer all patients with suspected liver disease or complications to a doctor.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Assess need for pain control.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Check on frequency of bowel movements and if less than or greater than two stools / day advise doctor to adjust lactulose dose accordingly.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Ask patient if they have melaena stools.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Document presence of confusion and or changes in behaviour which may be signs of evolving hepatic encephalopathy.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Order a low salt diet in patients with ascites.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Ensure adequate nutrition (with epap supplements if necessary) for all patients with liver disease.</p>
</div></li>
</ul>
<h2 id="references">References</h2>
<p>Goldberg and Chopra 2017. Cirrhosis in adults: Overview of complications, general management, and prognosis. UpToDate Mar 2017.</p>
<p>Sanyal 2017. General principles of the management of variceal haemorrhage. UpToDate Feb 2017</p>
<p>Runyon 2015. Spontaneous bacterial peritonitis in adults: Diagnosis. UpToDate Aug 2015.</p>
<p>Runyon 2016. Spontaneous bacterial peritonitis in adults: Treatment and prophylaxis. UpToDate Jan 2016.</p>
<p>Ferenci 2015. Hepatic encephalopathy in adults: Clinical manifestations and diagnosis. Sept 2015.</p>
<p>Fenerci 2017. Hepatic encephalopathy in adults: Treatment. Aug 2017.</p>
<p>Runyon 2016. Hepatorenal syndrome. UpToDate June 2016.</p>
<p>Goldberg and Chopra 2016. Hepatopulmonary syndrome in adults: Prevalence, causes, clinical manifestations, and diagnosis. Dec 2016.</p>
<p>Such and Runyon 2017. Ascites in adults with cirrhosis: Initial therapy. June 2017.</p>
<table>
<thead>
<tr class="header">
<th><strong>Written by:</strong></th>
<th>Name: Amie Secka</th>
<th>Date: 6 June 2018</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Reviewed by:</strong></td>
<td>Name: Karen Forrest</td>
<td>Date: 14 June 2018</td>
</tr>
<tr class="even">
<td><strong>Version:</strong></td>
<td><strong>Change history:</strong></td>
<td><strong>Review due date:</strong></td>
</tr>
<tr class="odd">
<td>1.0</td>
<td>New document</td>
<td></td>
</tr>
<tr class="even">
<td>2.0</td>
<td>Adapted from previous guideline on CLD and format updated.</td>
<td>31 July 2020</td>
</tr>
<tr class="odd">
<td>2.1</td>
<td>Executive summary added</td>
<td>31 July 2020</td>
</tr>
<tr class="even">
<td>Review Comments (<em>if applicable)</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</article>
</body>
</html>
